title: Copolymer 1 inhibits experimental autoimmune uveoretinitis.
abstract: Copolymer 1 (Cop 1) inhibits experimental allergic encephalomyelitis induced by a variety of myelin proteins, but has been found ineffective so far in inhibiting other experimental autoimmune diseases such as diabetes or arthritis. Here, we report for the first time that Cop I inhibits the development of experimental autoimmune uveoretinitis, induced in mice by interphotoreceptor retinoid-binding protein (IRBP). Pooled data of three experiments showed that treatment with Cop 1, at 0.5 mg/mouse, reduced the disease severity by 53% ( p = 0.0002). Cop 1 treatment also inhibited the proliferation and the production of cytokines by lymph node cells in response to IRBP and moderately reduced the antibody response to this antigen. The possible mechanisms of EAU inhibition by Cop 1 are discussed.
authors.affiliation: National Eye Institute, NIH, Bethesda, MD 20892-1857, USA.
authors.forename: M
authors.initials: M
authors.lastname: Zhang
authors.forename: C C
authors.initials: CC
authors.lastname: Chan
authors.forename: B
authors.initials: B
authors.lastname: Vistica
authors.forename: V
authors.initials: V
authors.lastname: Hung
authors.forename: B
authors.initials: B
authors.lastname: Wiggert
authors.forename: I
authors.initials: I
authors.lastname: Gery
mesh_terms: D000818:Animals; D001323:Autoantibodies / Q000097:blood; D001327:Autoimmune Diseases / Q000097:blood / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D002478:Cells, Cultured; D016207:Cytokines / Q000096:biosynthesis; D005128:Eye Diseases / Q000276:immunology / Q000517:prevention & control; D005136:Eye Proteins; D005260:Female; D000068717:Glatiramer Acetate; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008198:Lymph Nodes / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D051379:Mice; D010455:Peptides / Q000008:administration & dosage*; D012173:Retinitis / Q000097:blood / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D012177:Retinol-Binding Proteins / Q000276:immunology; D014605:Uveitis / Q000097:blood / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D000099214:Retinol-Binding Proteins, Interstitial
chemical_list: D001323:Autoantibodies; D016207:Cytokines; D005136:Eye Proteins; D000068717:Glatiramer Acetate; D007166:Immunosuppressive Agents; D010455:Peptides; D012177:Retinol-Binding Proteins; D000099214:Retinol-Binding Proteins, Interstitial